Ainos (AIMD) Competitors $3.46 -0.36 (-9.42%) As of 08/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. COEP, LVTX, SLGL, STTK, OVID, HYPD, ENLV, KPTI, RANI, and LIANShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Coeptis Therapeutics (COEP), LAVA Therapeutics (LVTX), Sol-Gel Technologies (SLGL), Shattuck Labs (STTK), Ovid Therapeutics (OVID), Hyperion DeFi (HYPD), Enlivex Therapeutics (ENLV), Karyopharm Therapeutics (KPTI), Rani Therapeutics (RANI), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Its Competitors Coeptis Therapeutics LAVA Therapeutics Sol-Gel Technologies Shattuck Labs Ovid Therapeutics Hyperion DeFi Enlivex Therapeutics Karyopharm Therapeutics Rani Therapeutics LianBio Coeptis Therapeutics (NASDAQ:COEP) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Do institutionals & insiders have more ownership in COEP or AIMD? 13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 10.4% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, COEP or AIMD? Coeptis Therapeutics has higher revenue and earnings than Ainos. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis Therapeutics$62.87K780.78-$10.88M-$5.80-2.41Ainos$20K806.18-$14.86M-$4.99-0.69 Does the media refer more to COEP or AIMD? In the previous week, Ainos had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 6 mentions for Ainos and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.65 beat Ainos' score of 0.11 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Positive Ainos Neutral Is COEP or AIMD more profitable? Ainos' return on equity of -108.25% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -216.96% -113.00% Ainos N/A -108.25%-56.94% Which has more volatility and risk, COEP or AIMD? Coeptis Therapeutics has a beta of -0.59, indicating that its stock price is 159% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. SummaryAinos beats Coeptis Therapeutics on 7 of the 12 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.12M$2.55B$5.72B$9.79BDividend YieldN/A1.76%3.91%4.13%P/E Ratio-0.6922.4731.1425.06Price / Sales806.18510.42416.7890.80Price / CashN/A170.4436.7858.67Price / Book1.415.079.086.18Net Income-$14.86M$31.61M$3.26B$265.11M7 Day Performance8.81%25.12%7.39%4.22%1 Month Performance23.57%2.78%4.22%0.77%1 Year Performance1.62%10.98%30.30%24.69% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos0.5839 of 5 stars$3.46-9.4%N/A+1.6%$16.12M$20K-0.6940News CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeShort Interest ↑COEPCoeptis Therapeutics0.52 of 5 stars$11.05-4.3%N/A+246.0%$40.58MN/A-1.912Earnings ReportShort Interest ↑Gap UpLVTXLAVA Therapeutics2.1975 of 5 stars$1.51+2.4%$2.69+78.4%-15.1%$38.67M$11.98M-1.4560Earnings ReportUpcoming EarningsShort Interest ↓Gap DownHigh Trading VolumeSLGLSol-Gel Technologies2.9337 of 5 stars$13.75+2.5%$40.00+190.9%+258.4%$37.38M$11.54M-2.9350News CoveragePositive NewsEarnings ReportSTTKShattuck Labs3.5413 of 5 stars$0.99+33.3%$7.50+657.6%-70.2%$35.58M$5.72M-0.71100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeOVIDOvid Therapeutics4.2249 of 5 stars$0.500.0%$3.13+529.7%-14.2%$35.31M$570K-1.4260News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap UpHYPDHyperion DeFi0.3609 of 5 stars$5.40-14.1%$2.00-63.0%-89.2%$35.24M$60K-0.0940News CoverageEarnings ReportGap UpENLVEnlivex Therapeutics3.335 of 5 stars$1.39-6.1%$10.00+619.4%+44.4%$35MN/A-2.1170News CoverageShort Interest ↓Gap UpKPTIKaryopharm Therapeutics3.8584 of 5 stars$3.88-3.5%$37.40+863.9%-51.8%$34.73M$145.24M-0.29380Earnings ReportAnalyst ForecastAnalyst RevisionRANIRani Therapeutics3.178 of 5 stars$0.55-0.4%$7.33+1,243.1%-80.2%$34.64M$1.03M-0.55110Analyst UpgradeShort Interest ↓LIANLianBioN/A$0.05-2.4%N/A-81.0%$34.47MN/A-0.07110 Related Companies and Tools Related Companies COEP Competitors LVTX Competitors SLGL Competitors STTK Competitors OVID Competitors HYPD Competitors ENLV Competitors KPTI Competitors RANI Competitors LIAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access